Pharmaceutical News of the Week (June. 29th-July. 3rd) | PharmaSources.com - Updates on M&A, IPO and Others

Transactions

23. Vitrac, a subsidiary of JS InnoPharm, announced on June 29 that it obtained the global exclusive development and commercialization rights for TAS-119, an Aurora A kinase inhibitor, in the oncology field from Taiho, a Japanese oncology drug company, and completed the transfer of the IND technical data and license of TAS-119 in the U.S. to it. As an oncology candidate innovatively developed by Taiho, TAS-119 has been completed two phase 1 clinical studies in the U.S. and Europe.

24. Carmine Therapeutics announced on July 1 that it entered into a research collaboration agreement with Takeda to discover, develop and commercialize transformative non-viral gene therapies for two rare disease targets using Carmine Therapeutics’ REGENT technology, based on red blood cell extracellular vesicles.

25. Citryll announced on July 2 that it completed a total of EUR18.50 million financing led by Seventure (including Health for Life Capital II fund) and co-invested by Biogeneration Ventures (BGV) and original investors BOM Brabant Ventures, BrightGene, and ModiQuest. The funds will be used to advance Cityll’s preclinical and clinical development of CIT-013 therapeutic antibody, an inhibitor of neutrophil extracellular traps (NETs) and their formation (NETosis).

Listing

SSE

26. Junshi Biosciences gave an announcement on the IPO and listing on the STAR Market on the evening of June 30, according to which, the company determined the IPO issue price on the STAR Market as RMB55.50/share after the initial inquiry, with the corresponding “market value/R&D expenses” multiple of 51.11 and would conduct online and offline subscription on July 2.

HKEX

27. Immunotech Biopharm released a global offering prospectus on June 29, which mentions that it starts to offer shares from June 29 and plans to issue 100 million shares at HKD10.5-11/share, including 90 million shares (90%) under the Global Offering and 10 million shares (10%) under the Hong Kong, S.A.R., China Public Offering, with a fundraising scale of HKD1.05-1.1 billion, and additionally a 15% Over-allotment Option. The sponsors are CCB International and Guosen Securities, and the company is expected to be officially listed on the HKEX on July 10.

28. RemeGen filed an IPO application to the HKEX on June 29 according to Chapter 18A of the Listing Rules of the HKEX and planned to be listed on the Hong Kong, S.A.R., China Main Board, with Morgan Stanley, Huatai Financial, and JPMorgan Chase being its co-sponsors. Established in 2008, RemeGen is a biopharmaceutical company that is entering the commercialization stage.

Miscellaneous

29. On July 2, Antengene announced its appointment of Yu Zhinuan, Ph.D., as Corporate Vice President (CVP) of Biometrics and Regulatory Enabling Functions, who will be responsible for providing statistical leadership and strategic regulatory input and will report directly to Dr. Jay Mei, Chairman and CEO of Antengene.

Related News:

Pharmaceutical News of the Week (June. 29th-July. 3rd) | PharmaSources.com - Updates on R&D

About  the Author:    

Caicai, a Master of Pharmacy from Shanghai Jiaotong University, used to work in the Institute of Science and Technical Information. Currently as a practitioner in the drug surveillance system, she is good at interpreting industry regulations, pharmaceutical research developments, etc.

-----------------------------------------------------------------------
Editor's Note:

To become a freelance writer of PharmaSources.com,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@imsinoexpo.com.